Aviptadil/phentolamine launched as combination treatment for erectile dysfunction

Invicorp (aviptadil/phentolamine) is a new combination intracavernosal injection for the treatment of erectile dysfunction.

After suitable training, patients may self-inject Invicorp at home.

Invicorp provides fixed doses of two agents with complementary mechanisms of action: aviptadil, a vasoactive intestinal polypeptide and phentolamine, a short-acting alpha-adrenoceptor antagonist.

Further information
View Invicorp drug record
Summary of Product Characteristics
Manufacturer: Evolan Pharma

Aviptadil has a potent effect on the veno-occlusive mechanism, but little effect on arterial inflow, whereas phentolamine increases arterial blood flow with no effect on the veno-occlusive mechanism. Both drugs cause smooth muscle relaxation of the corpus cavernosa which increases cavernosal artery blood flow, producing an erection.

Patient satisfaction

Two studies of aviptadil/phentolamine intracavernosal injection were conducted in patients with predominantly non-psychogenic erectile dysfunction, using doses of 25 microgram/1mg or 25 microgram/2mg.

In the first study, 304 men completed the dose assessment phase and 195 entered the placebo-controlled phase. Response rates were 75.1% with the 25 microgram/1mg dose versus 12% with placebo (p<0.001) and 66.5% with the 25 microgram/2mg dose versus 0.3% with placebo (p<0.001).

The second study enrolled 236 men, of whom 171 were treated in the placebo-controlled phase. In total, 75% responded to the lower dose (vs 12% to placebo; p<0.001) and 66% responded to the higher dose (vs 18% to placebo; p<0.001).

Erections lasted for a median of 54–56 minutes. More than 80% of patients were satisfied with the drug and more than 90% with the auto-injector. Improved quality of life was reported by more than 80% of patients and more than 75% of partners.

Facial flushing

The principal adverse event of aviptadil/phentolamine intracavernosal injection was transient facial flushing, which accompanied 34% and 40% of injections in the two studies, respectively. There were three episodes of priapism in total, and no reports of post-injection pain; 16 patients withdrew because of adverse events.


Initial injections of Invicorp must be administered by trained healthcare professionals, but after training patients may self-administer at home.

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Already registered?
Sign in